Tag: Gpc4

Background We analyzed the reactions to first range treatment and clinical results of metastatic breasts cancer individuals treated with palliative doxorubicin/cyclophosphamide (AC) based on molecular tumor subtype. 42.9% for the HER2+ subgroup, and 56.5% for the TN subgroup. The progression-free success (PFS) in individuals with HER2+ and TN had been considerably shorter than in the…